{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:10:35Z","timestamp":1792674635756,"version":"4.5.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,2,22]],"date-time":"2016-02-22T00:00:00Z","timestamp":1456099200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s00259-016-3324-6","type":"journal-article","created":{"date-parts":[[2016,2,22]],"date-time":"2016-02-22T02:10:17Z","timestamp":1456107017000},"page":"1171-1182","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["Current status of PET imaging in Huntington\u2019s disease"],"prefix":"10.1007","volume":"43","author":[{"given":"Gennaro","family":"Pagano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Niccolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marios","family":"Politis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,22]]},"reference":[{"key":"3324_CR1","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/mds.25075","volume":"27","author":"T Pringsheim","year":"2012","unstructured":"Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N. The incidence and prevalence of Huntington\u2019s disease: a systematic review and meta-analysis. Mov Disord. 2012;27:1083\u201391.","journal-title":"Mov Disord"},{"key":"3324_CR2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"The Huntington's Disease Collaborative Research Group","year":"1993","unstructured":"The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell. 1993;72:971\u201383.","journal-title":"Cell"},{"issue":"4","key":"3324_CR3","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","volume":"10","author":"CA Ross","year":"2014","unstructured":"Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol. 2014;10(4):204\u201316.","journal-title":"Nat Rev Neurol"},{"key":"3324_CR4","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1073\/pnas.96.8.4604","volume":"96","author":"E Scherzinger","year":"1999","unstructured":"Scherzinger E, Sittler A, Schweiger K, Heiser V, Lurz R, Hasenbank R, et al. Self-assembly of polyglutamine containing huntingtin fragments into amyloid-like fibrils: implications for Huntington disease pathology. Proc Natl Acad Sci U S A. 1999;96:4604\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3324_CR5","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ajmg.b.30992","volume":"153B","author":"DR Langbehn","year":"2010","unstructured":"Langbehn DR, Hayden MR, Paulsen JS; PREDICT-HD Investigators of the Huntington Study Group. CAG repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet. 2010;153B:397\u2013408.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"3324_CR6","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/mds.26011","volume":"29","author":"R Reilmann","year":"2014","unstructured":"Reilmann R, Leavitt BR, Ross CA. Diagnostic criteria for Huntington\u2019s disease based on natural history. Mov Disord. 2014;29:1335\u201341.","journal-title":"Mov Disord"},{"key":"3324_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-19285-7_1","volume":"217","author":"U R\u00fcb","year":"2015","unstructured":"R\u00fcb U, Vonsattel JP, Heinsen H, Korf HW. The neuropathology of Huntington\u00b4s disease: classical findings, recent developments and correlation to functional neuroanatomy. Adv Anat Embryol Cell Biol. 2015;217:1\u2013146.","journal-title":"Adv Anat Embryol Cell Biol"},{"issue":"9","key":"3324_CR8","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00415-012-6428-3","volume":"259","author":"M Politis","year":"2012","unstructured":"Politis M, Piccini P. Positron emission tomography imaging in neurological disorders. J Neurol. 2012;259(9):1769\u201380.","journal-title":"J Neurol"},{"issue":"12","key":"3324_CR9","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nrneurol.2014.205","volume":"10","author":"M Politis","year":"2014","unstructured":"Politis M. Neuroimaging in Parkinson disease: from research setting to clinical practice. Nat Rev Neurol. 2014;10(12):708\u201322.","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"3324_CR10","first-page":"323","volume":"3","author":"C Loane","year":"2011","unstructured":"Loane C, Politis M. Positron emission tomography neuroimaging in Parkinson\u2019s disease. Am J Transl Res. 2011;3(4):323\u201341.","journal-title":"Am J Transl Res"},{"issue":"9","key":"3324_CR11","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1007\/s00415-015-7711-x","volume":"262","author":"L Rocchi","year":"2015","unstructured":"Rocchi L, Niccolini F, Politis M. Recent imaging advances in neurology. J Neurol. 2015;262(9):2182\u201394.","journal-title":"J Neurol"},{"issue":"6","key":"3324_CR12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.4329\/wjr.v6.i6.301","volume":"6","author":"F Niccolini","year":"2014","unstructured":"Niccolini F, Politis M. Neuroimaging in Huntington\u2019s disease. World J Radiol. 2014;6(6):301\u201312.","journal-title":"World J Radiol"},{"key":"3324_CR13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/jcbfm.1981.4","volume":"1","author":"L Sokoloff","year":"1981","unstructured":"Sokoloff L. Localization of functional activity in the central nervous system by measurement of glucose utilization with radioactive deoxyglucose. J Cereb Blood Flow Metab. 1981;1:7\u201336.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"Pt 9","key":"3324_CR14","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/brain\/120.9.1553","volume":"120","author":"P Bartenstein","year":"1997","unstructured":"Bartenstein P, Weindl A, Spiegel S, Boecker H, Wenzel R, Ceballos-Baumann AO, et al. Central motor processing in Huntington\u2019s disease. A PET study. Brain. 1997;120(Pt 9):1553\u201367.","journal-title":"Brain"},{"issue":"Pt 9","key":"3324_CR15","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/brain\/120.9.1569","volume":"120","author":"RA Weeks","year":"1997","unstructured":"Weeks RA, Ceballos-Baumann A, Piccini P, Boecker H, Harding AE, Brooks DJ. Cortical control of movement in Huntington\u2019s disease. A PET activation study. Brain. 1997;120(Pt 9):1569\u201378.","journal-title":"Brain"},{"key":"3324_CR16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bandl.2009.05.004","volume":"110","author":"E Lepron","year":"2009","unstructured":"Lepron E, P\u00e9ran P, Cardebat D, D\u00e9monet JF. A PET study of word generation in Huntington\u2019s disease: effects of lexical competition and verb\/noun category. Brain Lang. 2009;110:49\u201360.","journal-title":"Brain Lang"},{"issue":"Pt 6","key":"3324_CR17","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/brain\/119.6.2085","volume":"119","author":"A Antonini","year":"1996","unstructured":"Antonini A, Leenders KL, Spiegel R, Meier D, Vontobel P, Weigell-Weber M, et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington\u2019s disease. Brain. 1996;119(Pt 6):2085\u201395.","journal-title":"Brain"},{"key":"3324_CR18","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM198702123160701","volume":"316","author":"JC Mazziotta","year":"1987","unstructured":"Mazziotta JC, Phelps ME, Pahl JJ, Huang SC, Baxter LR, Riege WH, et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington\u2019s disease. N Engl J Med. 1987;316:357\u201362.","journal-title":"N Engl J Med"},{"issue":"Pt 5","key":"3324_CR19","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1093\/brain\/113.5.1405","volume":"113","author":"T Kuwert","year":"1990","unstructured":"Kuwert T, Lange HW, Langen KJ, Herzog H, Aulich A, Feinendegen LE. Cortical and subcortical glucose consumption measured by PET in patients with Huntington\u2019s disease. Brain. 1990;113(Pt 5):1405\u201323.","journal-title":"Brain"},{"key":"3324_CR20","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/ana.410200305","volume":"20","author":"AB Young","year":"1986","unstructured":"Young AB, Penney JB, Starosta-Rubinstein S, Markel DS, Berent S, Giordani B, et al. PET scan investigations of Huntington\u2019s disease: cerebral metabolic correlates of neurological features and functional decline. Ann Neurol. 1986;20:296\u2013303.","journal-title":"Ann Neurol"},{"key":"3324_CR21","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/ana.410230603","volume":"23","author":"S Berent","year":"1988","unstructured":"Berent S, Giordani B, Lehtinen S, Markel D, Penney JB, Buchtel HA, et al. Positron emission tomographic scan investigations of Huntington\u2019s disease: cerebral metabolic correlates of cognitive function. Ann Neurol. 1988;23:541\u20136.","journal-title":"Ann Neurol"},{"key":"3324_CR22","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1212\/WNL.36.7.888","volume":"36","author":"MR Hayden","year":"1986","unstructured":"Hayden MR, Martin WR, Stoessl AJ, Clark C, Hollenberg S, Adam MJ, et al. Positron emission tomography in the early diagnosis of Huntington\u2019s disease. Neurology. 1986;36:888\u201394.","journal-title":"Neurology"},{"key":"3324_CR23","first-page":"215","volume":"47","author":"A Ciarmiello","year":"2006","unstructured":"Ciarmiello A, Cannella M, Lastoria S, Simonelli M, Frati L, Rubinsztein DC, et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington\u2019s disease. J Nucl Med. 2006;47:215\u201322.","journal-title":"J Nucl Med"},{"key":"3324_CR24","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1007\/s00259-012-2114-z","volume":"39","author":"A Ciarmiello","year":"2012","unstructured":"Ciarmiello A, Giovacchini G, Orobello S, Bruselli L, Elifani F, Squitieri F. 18F-FDG PET uptake in the pre-Huntington disease caudate affects the time-to-onset independently of CAG expansion size. Eur J Nucl Med Mol Imaging. 2012;39:1030\u20136.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3324_CR25","unstructured":"Feigin A, Leenders KL, Moeller JR, Missimer J, Kuenig G, Spetsieris P, et al. Metabolic network abnormalities in early Huntington\u2019s disease: an [18F]FDG PET study. J Nucl Med. 2001;42:1591\u20135."},{"key":"3324_CR26","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1093\/brain\/awm217","volume":"130","author":"A Feigin","year":"2007","unstructured":"Feigin A, Tang C, Ma Y, Mattis P, Zgaljardic D, Guttman M, et al. Thalamic metabolism and symptom onset in preclinical Huntington\u2019s disease. Brain. 2007;130:2858\u201367.","journal-title":"Brain"},{"key":"3324_CR27","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1172\/JCI45646","volume":"121","author":"D Eidelberg","year":"2011","unstructured":"Eidelberg D, Surmeier DJ. Brain networks in Huntington disease. J Clin Invest. 2011;121:484\u201392.","journal-title":"J Clin Invest"},{"key":"3324_CR28","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1172\/JCI69411","volume":"123","author":"CC Tang","year":"2013","unstructured":"Tang CC, Feigin A, Ma Y, Habeck C, Paulsen JS, Leenders KL, et al. Metabolic network as a progression biomarker of premanifest Huntington\u2019s disease. J Clin Invest. 2013;123:4076\u201388.","journal-title":"J Clin Invest"},{"issue":"4","key":"3324_CR29","first-page":"323","volume":"33","author":"A Schrag","year":"1999","unstructured":"Schrag A, Quinn N. Disorders of the basal ganglia and their modern management. J R Coll Physicians Lond. 1999;33(4):323\u20137.","journal-title":"J R Coll Physicians Lond"},{"issue":"45","key":"3324_CR30","doi-asserted-by":"crossref","first-page":"11603","DOI":"10.1523\/JNEUROSCI.1840-08.2008","volume":"28","author":"M Day","year":"2008","unstructured":"Day M, Wokosin D, Plotkin JL, Tian X, Surmeier DJ. Differential excitability and modulation of striatal medium spiny neuron dendrites. J Neurosci. 2008;28(45):11603\u201314.","journal-title":"J Neurosci"},{"issue":"3 Suppl","key":"3324_CR31","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1017\/S0317167100037896","volume":"14","author":"WR Martin","year":"1987","unstructured":"Martin WR, Hayden MR. Cerebral glucose and dopa metabolism in movement disorders. Can J Neurol Sci. 1987;14(3 Suppl):448\u201351.","journal-title":"Can J Neurol Sci"},{"key":"3324_CR32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/mds.870010110","volume":"1","author":"KL Leenders","year":"1986","unstructured":"Leenders KL, Frackowiak RS, Quinn N, Marsden CD. Brain energy metabolism and dopaminergic function in Huntington\u2019s disease measured in vivo using positron emission tomography. Mov Disord. 1986;1:69\u201377.","journal-title":"Mov Disord"},{"issue":"Pt 3","key":"3324_CR33","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/brain\/120.3.503","volume":"120","author":"N Ginovart","year":"1997","unstructured":"Ginovart N, Lundin A, Farde L, Halldin C, Backman L, Swahn CG, et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington\u2019s disease. Brain. 1997;120(Pt 3):503\u201314.","journal-title":"Brain"},{"issue":"9","key":"3324_CR34","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1212\/WNL.54.9.1753","volume":"54","author":"NI Bohnen","year":"2000","unstructured":"Bohnen NI, Koeppe RA, Meyer P, Ficaro E, Wernette K, Kilbourn MR, et al. Decreased striatal monoaminergic terminals in Huntington disease. Neurology. 2000;54(9):1753\u20139.","journal-title":"Neurology"},{"key":"3324_CR35","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/hbm.21134","volume":"32","author":"M Esmaeilzadeh","year":"2011","unstructured":"Esmaeilzadeh M, Farde L, Karlsson P, Varrone A, Halldin C, Waters S, et al. Extrastriatal dopamine D(2) receptor binding in Huntington\u2019s disease. Hum Brain Mapp. 2011;32:1626\u201336.","journal-title":"Hum Brain Mapp"},{"key":"3324_CR36","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/BF02191583","volume":"243","author":"G Sedvall","year":"1994","unstructured":"Sedvall G, Karlsson P, Lundin A, Anvret M, Suhara T, Halldin C, et al. Dopamine D1 receptor number \u2013 a sensitive PET marker for early brain degeneration in Huntington\u2019s disease. Eur Arch Psychiatry Clin Neurosci. 1994;243:249\u201355.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"Pt 12","key":"3324_CR37","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1093\/brain\/122.12.2353","volume":"122","author":"TC Andrews","year":"1999","unstructured":"Andrews TC, Weeks RA, Turjanski N, Gunn RN, Watkins LH, Sahakian B, et al. Huntington\u2019s disease progression. PET and clinical observations. Brain. 1999;122(Pt 12):2353\u201363.","journal-title":"Brain"},{"key":"3324_CR38","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1212\/01.wnl.0000176071.08694.cc","volume":"65","author":"JC Oostrom van","year":"2005","unstructured":"van Oostrom JC, Maguire RP, Verschuuren-Bemelmans CC, Veenma-van der Duin L, Pruim J, Roos RA, et al. Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease. Neurology. 2005;65:941\u20133.","journal-title":"Neurology"},{"issue":"Pt 3","key":"3324_CR39","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/brain\/118.3.689","volume":"118","author":"N Turjanski","year":"1995","unstructured":"Turjanski N, Weeks R, Dolan R, Harding AE, Brooks DJ. Striatal D1 and D2 receptor binding in patients with Huntington\u2019s disease and other choreas. A PET study. Brain. 1995;118(Pt 3):689\u201396.","journal-title":"Brain"},{"key":"3324_CR40","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/brain\/awg119","volume":"126","author":"N Pavese","year":"2003","unstructured":"Pavese N, Andrews TC, Brooks DJ, Ho AK, Rosser AE, Barker RA, et al. Progressive striatal and cortical dopamine receptor dysfunction in Huntington\u2019s disease: a PET study. Brain. 2003;126:1127\u201335.","journal-title":"Brain"},{"issue":"Pt 12","key":"3324_CR41","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1093\/brain\/120.12.2207","volume":"120","author":"L B\u00e4ckman","year":"1997","unstructured":"B\u00e4ckman L, Robins-Wahlin TB, Lundin A, Ginovart N, Farde L. Cognitive deficits in Huntington\u2019s disease are predicted by dopaminergic PET markers and brain volumes. Brain. 1997;120(Pt 12):2207\u201317.","journal-title":"Brain"},{"key":"3324_CR42","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.nbd.2009.10.015","volume":"37","author":"N Pavese","year":"2010","unstructured":"Pavese N, Politis M, Tai YF, Barker RA, Tabrizi SJ, Mason SL, et al. Cortical dopamine dysfunction in symptomatic and premanifest Huntington\u2019s disease gene carriers. Neurobiol Dis. 2010;37:356\u201361.","journal-title":"Neurobiol Dis"},{"issue":"Pt 7","key":"3324_CR43","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/brain\/121.7.1343","volume":"121","author":"AD Lawrence","year":"1998","unstructured":"Lawrence AD, Weeks RA, Brooks DJ, Andrews TC, Watkins LH, Harding AE, et al. The relationship between striatal dopamine receptor binding and cognitive performance in Huntington\u2019s disease. Brain. 1998;121(Pt 7):1343\u201355.","journal-title":"Brain"},{"key":"3324_CR44","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1093\/brain\/awn244","volume":"131","author":"M Politis","year":"2008","unstructured":"Politis M, Pavese N, Tai YF, Tabrizi SJ, Barker RA, Piccini P. Hypothalamic involvement in Huntington\u2019s disease: an in vivo PET study. Brain. 2008;131:2860\u20139.","journal-title":"Brain"},{"key":"3324_CR45","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ana.410430216","volume":"43","author":"A Antonini","year":"1998","unstructured":"Antonini A, Leenders KL, Eidelberg D. [11C]raclopride-PET studies of the Huntington\u2019s disease rate of progression: relevance of the trinucleotide repeat length. Ann Neurol. 1998;43:253\u20135.","journal-title":"Ann Neurol"},{"key":"3324_CR46","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3389\/fnins.2015.00173","volume":"9","author":"G Dijk van","year":"2015","unstructured":"van Dijk G, van Heijningen S, Reijne AC, Nyakas C, van der Zee EA, Eisel UL. Integrative neurobiology of metabolic diseases, neuroinflammation, and neurodegeneration. Front Neurosci. 2015;9:173.","journal-title":"Front Neurosci"},{"key":"3324_CR47","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3389\/fphar.2012.00096","volume":"3","author":"M Politis","year":"2012","unstructured":"Politis M, Su P, Piccini P. Imaging of microglia in patients with neurodegenerative disorders. Front Pharmacol. 2012;3:96.","journal-title":"Front Pharmacol"},{"key":"3324_CR48","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1385\/MN:27:2:163","volume":"27","author":"H Nakanishi","year":"2003","unstructured":"Nakanishi H. Microglial functions and proteases. Mol Neurobiol. 2003;27:163\u201376.","journal-title":"Mol Neurobiol"},{"issue":"4","key":"3324_CR49","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s12149-015-0948-8","volume":"29","author":"K Hatano","year":"2015","unstructured":"Hatano K, Sekimata K, Yamada T, Abe J, Ito K, Ogawa M, et al. Radiosynthesis and in vivo evaluation of two imidazopyridineacetamides, [(11)C]CB184 and [(11)C]CB190, as a PET tracer for 18 kDa translocator protein: direct comparison with [(11)C](R)-PK11195. Ann Nucl Med. 2015;29(4):325\u201335.","journal-title":"Ann Nucl Med"},{"issue":"2","key":"3324_CR50","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.neuroimage.2011.12.078","volume":"60","author":"Q Guo","year":"2012","unstructured":"Guo Q, Owen DR, Rabiner EA, Turkheimer FE, Gunn RN. Identifying improved TSPO PET imaging probes through biomathematics: the impact of multiple TSPO binding sites in vivo. Neuroimage. 2012;60(2):902\u201310. doi: 10.1016\/j.neuroimage.2011.12.078 .","journal-title":"Neuroimage"},{"key":"3324_CR51","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1212\/01.wnl.0000222734.56412.17","volume":"66","author":"N Pavese","year":"2006","unstructured":"Pavese N, Gerhard A, Tai YF, Ho AK, Turkheimer F, Barker RA, et al. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology. 2006;66:1638\u201343.","journal-title":"Neurology"},{"key":"3324_CR52","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/brain\/awm044","volume":"130","author":"YF Tai","year":"2007","unstructured":"Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, et al. Microglial activation in presymptomatic Huntington\u2019s disease gene carriers. Brain. 2007;130:1759\u201366.","journal-title":"Brain"},{"key":"3324_CR53","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/hbm.21008","volume":"32","author":"M Politis","year":"2011","unstructured":"Politis M, Pavese N, Tai YF, Kiferle L, Mason SL, Brooks DJ, et al. Microglial activation in regions related to cognitive function predicts disease onset in Huntington\u2019s disease: a multimodal imaging study. Hum Brain Mapp. 2011;32:258\u201370.","journal-title":"Hum Brain Mapp"},{"key":"3324_CR54","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.nbd.2015.08.011","volume":"83","author":"M Politis","year":"2015","unstructured":"Politis M, Lahiri N, Niccolini F, Su P, Wu K, Giannetti P, et al. Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington\u2019s disease gene carriers. Neurobiol Dis. 2015;83:115\u201321. doi: 10.1016\/j.nbd.2015.08.011 .","journal-title":"Neurobiol Dis"},{"key":"3324_CR55","doi-asserted-by":"crossref","first-page":"10460","DOI":"10.1523\/JNEUROSCI.2518-08.2008","volume":"28","author":"A Nishi","year":"2008","unstructured":"Nishi A, Kuroiwa M, Miller DB, O'Callaghan JP, Bateup HS, Shuto T, et al. Distinct roles of PDE4 and PDE10A in the regulation of cAMP\/PKA signaling in the striatum. J Neurosci. 2008;28:10460\u201371.","journal-title":"J Neurosci"},{"key":"3324_CR56","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/978-3-7091-0932-8_18","volume":"970","author":"JA Girault","year":"2012","unstructured":"Girault JA. Integrating neurotransmission in striatal medium spiny neurons. Adv Exp Med Biol. 2012;970:407\u201329.","journal-title":"Adv Exp Med Biol"},{"key":"3324_CR57","doi-asserted-by":"crossref","unstructured":"Giampa C, Laurenti D, Anzilotti S, Bernardi G, Menniti FS, Fusco FR. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6\/2 mouse model of Huntington\u2019s disease. PLoS One. 2010;5(10):e13417.","DOI":"10.1371\/journal.pone.0013417"},{"key":"3324_CR58","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.neuroscience.2003.11.009","volume":"123","author":"AL Hebb","year":"2004","unstructured":"Hebb AL, Robertson HA, Denovan-Wright EM. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington\u2019s disease transgenic mice prior to the onset of motor symptoms. Neuroscience. 2004;123:967\u201381.","journal-title":"Neuroscience"},{"issue":"3","key":"3324_CR59","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1212\/WNL.0000000000000037","volume":"82","author":"R Ahmad","year":"2014","unstructured":"Ahmad R, Bourgeois S, Postnov A, Schmidt ME, Bormans G, Van Laere K, et al. PET imaging shows loss of striatal PDE10A in patients with Huntington disease. Neurology. 2014;82(3):279\u201381.","journal-title":"Neurology"},{"issue":"12","key":"3324_CR60","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jamaneurol.2014.1954","volume":"71","author":"DS Russell","year":"2014","unstructured":"Russell DS, Barret O, Jennings DL, Friedman JH, Tamagnan GD, Thomae D, et al. The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease. JAMA Neurol. 2014;71(12):1520\u20138.","journal-title":"JAMA Neurol"},{"key":"3324_CR61","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1093\/brain\/awv214","volume":"138","author":"F Niccolini","year":"2015","unstructured":"Niccolini F, Haider S, Marques T, Muhlert N, Tziortzi A, Searle G, et al. Altered PDE10A expression detectable early before symptomatic onset in Huntington\u2019s disease. Brain. 2015;138:3016\u201329. doi: 10.1093\/brain\/awv214 .","journal-title":"Brain"},{"issue":"1","key":"3324_CR62","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.nbd.2004.05.008","volume":"17","author":"M Gianfriddo","year":"2004","unstructured":"Gianfriddo M, Melani A, Turchi D, Giovannini MG, Pedata F. Adenosine and glutamate extracellular concentrations and mitogen activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow. Neurobiol Dis. 2004;17(1):77\u201388.","journal-title":"Neurobiol Dis"},{"issue":"3","key":"3324_CR63","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1471-4159.2005.03169.x","volume":"94","author":"A Bauer","year":"2005","unstructured":"Bauer A, Zilles K, Matusch A, Holzmann C, Riess O, von Horsten S. Regional and subtype selective changes of neurotransmitter receptor density in a rat transgenic for the Huntington\u2019s disease mutation. J Neurochem. 2005;94(3):639\u201350.","journal-title":"J Neurochem"},{"issue":"6","key":"3324_CR64","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1007\/s00259-014-2724-8","volume":"41","author":"A Matusch","year":"2014","unstructured":"Matusch A, Saft C, Elmenhorst D, Kraus PH, Gold R, Hartung HP, et al. Cross sectional PET study of cerebral adenosine A1 receptors in premanifest and manifest Huntington\u2019s disease. Eur J Nucl Med Mol Imaging. 2014;41(6):1210\u201320.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3324_CR65","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0006-8993(91)90970-7","volume":"547","author":"M Herkenham","year":"1991","unstructured":"Herkenham M, Lynn AB, de Costa BR, Richfield EK. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res. 1991;547:267\u201374.","journal-title":"Brain Res"},{"key":"3324_CR66","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1460-9568.1997.tb01390.x","volume":"9","author":"M Glass","year":"1997","unstructured":"Glass M, Brotchie JM, Maneuf YP. Modulation of neurotransmission by cannabinoids in the basal ganglia. Eur J Neurosci. 1997;9:199\u2013203.","journal-title":"Eur J Neurosci"},{"key":"3324_CR67","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0306-4522(00)00008-7","volume":"97","author":"M Glass","year":"2000","unstructured":"Glass M, Dragunow M, Faull RL. The pattern of neurodegeneration in Huntington\u2019s disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington\u2019s disease. Neuroscience. 2000;97:505\u201319.","journal-title":"Neuroscience"},{"issue":"2","key":"3324_CR68","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/ana.410180207","volume":"18","author":"PJ Whitehouse","year":"1985","unstructured":"Whitehouse PJ, Trifiletti RR, Jones BE, Folstein S, Price DL, Snyder SH, et al. Neurotransmitter receptor alterations in Huntington\u2019s disease: autoradiographic and homogenate studies with special reference to benzodiazepine receptor complexes. Ann Neurol. 1985;18(2):202\u201310.","journal-title":"Ann Neurol"},{"issue":"1","key":"3324_CR69","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0006-8993(79)90060-X","volume":"165","author":"TD Reisine","year":"1979","unstructured":"Reisine TD, Wastek GJ, Speth RC, Bird ED, Yamamura HI. Alterations in the benzodiazepine receptor of Huntington\u2019s diseased human brain. Brain Res. 1979;165(1):183\u20137.","journal-title":"Brain Res"},{"key":"3324_CR70","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/cne.901870203","volume":"187","author":"CE Ribac","year":"1979","unstructured":"Ribac CE, Vaughn JE, Roberts E. The GABA neurons and their axon terminals in rat corpus striatum as demonstrated by GAD immunocytochemistry. J Comp Neurol. 1979;187:261\u201384.","journal-title":"J Comp Neurol"},{"issue":"1","key":"3324_CR71","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/ana.410340114","volume":"34","author":"VA Holthoff","year":"1993","unstructured":"Holthoff VA, Koeppe RA, Frey KA, Penney JB, Markel DS, Kuhl DE, et al. Positron emission tomography measures of benzodiazepine receptors in Huntington\u2019s disease. Ann Neurol. 1993;34(1):76\u201381.","journal-title":"Ann Neurol"},{"issue":"5","key":"3324_CR72","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/1531-8249(200005)47:5<644::AID-ANA13>3.0.CO;2-C","volume":"47","author":"G K\u00fcnig","year":"2000","unstructured":"K\u00fcnig G, Leenders KL, Sanchez-Pernaute R, Antonini A, Vontobel P, Verhagen A, et al. Benzodiazepine receptor binding in Huntington\u2019s disease: [11C]flumazenil uptake measured using positron emission tomography. Ann Neurol. 2000;47(5):644\u20138.","journal-title":"Ann Neurol"},{"key":"3324_CR73","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2967\/jnumed.110.077156","volume":"51","author":"K Laere Van","year":"2010","unstructured":"Van Laere K, Casteels C, Dhollander I, Goffin K, Grachev I, Bormans G, et al. Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo. J Nucl Med. 2010;51:1413\u20137.","journal-title":"J Nucl Med"},{"key":"3324_CR74","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/hmg\/ddm133","volume":"16","author":"A Kuhn","year":"2007","unstructured":"Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C, et al. Mutant huntingtin\u2019s effects on striatal gene expression in mice recapitulate changes observed in human Huntington\u2019s disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet. 2007;16:1845\u201361.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"3324_CR75","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/ana.410310412","volume":"31","author":"RL Albin","year":"1992","unstructured":"Albin RL, Reiner A, Anderson KD, Dure 4th LS, Handelin B, Balfour R, et al. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington\u2019s disease. Ann Neurol. 1992;31(4):425\u201330.","journal-title":"Ann Neurol"},{"key":"3324_CR76","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/0006-8993(86)90946-7","volume":"378","author":"BR Seizinger","year":"1986","unstructured":"Seizinger BR, Liebisch DC, Kish SJ, Arendt RM, Hornykiewicz O, Herz A. Opioid peptides in Huntington's disease: alterations in prodynorphin and proenkephalin system. Brain Res. 1986;378:405\u20138.","journal-title":"Brain Res"},{"key":"3324_CR77","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1097\/00004647-199709000-00003","volume":"17","author":"RA Weeks","year":"1997","unstructured":"Weeks RA, Cunningham VJ, Piccini P, Waters S, Harding AE, Brooks DJ. 11C-diprenorphine binding in Huntington\u2019s disease: a comparison of region of interest analysis with statistical parametric mapping. J Cereb Blood Flow Metab. 1997;17:943\u20139.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"12","key":"3324_CR78","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1016\/j.neurobiolaging.2014.06.010","volume":"35","author":"M Ooms","year":"2014","unstructured":"Ooms M, Rietjens R, Rangarajan JR, Vunckx K, Valdeolivas S, Maes F, et al. Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6\/2 Huntington mice. Neurobiol Aging. 2014;35(12):2858\u201369.","journal-title":"Neurobiol Aging"},{"key":"3324_CR79","first-page":"21","volume":"9","author":"H Shin","year":"2013","unstructured":"Shin H, Kim MH, Lee SJ, Lee KH, Kim MJ, Kim JS, et al. Decreased metabolism in the cerebral cortex in early-stage Huntington\u2019s disease: a possible biomarker of disease progression? Int J Clin Neuropsychol. 2013;9:21\u20135.","journal-title":"Int J Clin Neuropsychol"},{"key":"3324_CR80","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1073\/pnas.85.15.5733","volume":"85","author":"A Reiner","year":"1988","unstructured":"Reiner A, Albin RL, Anderson KD, D\u2019Amato CJ, Penney JB, Young AB. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A. 1988;85:5733\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3324_CR81","unstructured":"Russell D, Jennings D, Barret O, Tamagnan G, Carroll V, Alagille D, et al. Longitudinal assessment of PDE10 in Huntington disease (HD) using [18F]MNI-659 PET imaging. J Nucl Med. 2015;56 Suppl 3:87."},{"key":"3324_CR82","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1001\/archneurol.2011.167","volume":"68","author":"MR Sabuncu","year":"2011","unstructured":"Sabuncu MR, Desikan RS, Sepulcre J, Yeo BT, Liu H, Schmansky NJ, et al. The dynamics of cortical and hippocampal atrophy in Alzheimer disease. Arch Neurol. 2011;68:1040\u20138.","journal-title":"Arch Neurol"},{"key":"3324_CR83","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1212\/WNL.58.5.695","volume":"58","author":"HD Rosas","year":"2002","unstructured":"Rosas HD, Liu AK, Hersch S, Glessner M, Ferrante RJ, Salat DH, et al. Regional and progressive thinning of the cortical ribbon in Huntington\u2019s disease. Neurology. 2002;58:695\u2013701.","journal-title":"Neurology"},{"key":"3324_CR84","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/brain\/awn025","volume":"131","author":"HD Rosas","year":"2008","unstructured":"Rosas HD, Salat DH, Lee SY, Zaleta AK, Pappu V, Fischl B, et al. Cerebral cortex and the clinical expression of Huntington\u2019s disease: complexity and heterogeneity. Brain. 2008;131:1057\u201368.","journal-title":"Brain"},{"key":"3324_CR85","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/ana.20121","volume":"55","author":"SA Reading","year":"2004","unstructured":"Reading SA, Dziorny AC, Peroutka LA, Schreiber M, Gourley LM, Yallapragada V, et al. Functional brain changes in presymptomatic Huntington\u2019s disease. Ann Neurol. 2004;55:879\u201383.","journal-title":"Ann Neurol"},{"key":"3324_CR86","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1136\/jnnp.73.6.678","volume":"73","author":"AE Rosser","year":"2002","unstructured":"Rosser AE, Barker RA, Harrower T, Watts C, Farrington M, Ho AK, et al. Unilateral transplantation of human primary fetal tissue in four patients with Huntington\u2019s disease: NESTUK safety report ISRCTN no 36485475. J Neurol Neurosurg Psychiatry. 2002;73:678\u201385.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3324_CR87","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/ana.20564","volume":"58","author":"S Furtado","year":"2005","unstructured":"Furtado S, Sossi V, Hauser RA, Samii A, Schulzer M, Murphy CB, et al. Positron emission tomography after fetal transplantation in Huntington\u2019s disease. Ann Neurol. 2005;58:331\u20137.","journal-title":"Ann Neurol"},{"key":"3324_CR88","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/jnnp-2012-302441","volume":"84","author":"RA Barker","year":"2013","unstructured":"Barker RA, Mason SL, Harrower TP, Swain RA, Ho AK, Sahakian BJ, et al. The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington\u2019s disease. J Neurol Neurosurg Psychiatry. 2013;84:657\u201365.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3324_CR89","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(00)03310-9","volume":"356","author":"AC Bachoud-L\u00e9vi","year":"2000","unstructured":"Bachoud-L\u00e9vi AC, R\u00e9my P, Nguyen JP, Brugi\u00e8res P, Lefaucheur JP, Bourdet C, et al. Motor and cognitive improvements in patients with Huntington\u2019s disease after neural transplantation. Lancet. 2000;356:1975\u20139.","journal-title":"Lancet"},{"key":"3324_CR90","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/brain\/awh003","volume":"127","author":"V Gaura","year":"2004","unstructured":"Gaura V, Bachoud-L\u00e9vi AC, Ribeiro MJ, Nguyen JP, Frouin V, Baudic S, et al. Striatal neural grafting improves cortical metabolism in Huntington\u2019s disease patients. Brain. 2004;127:65\u201372.","journal-title":"Brain"},{"key":"3324_CR91","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0079-6123(10)84010-5","volume":"184","author":"M Politis","year":"2010","unstructured":"Politis M, Piccini P. Brain imaging after neural transplantation. Prog Brain Res. 2010;184:193\u2013203.","journal-title":"Prog Brain Res"},{"key":"3324_CR92","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1741-7015-9-50","volume":"9","author":"M Politis","year":"2011","unstructured":"Politis M. Optimizing functional imaging protocols for assessing the outcome of fetal cell transplantation in Parkinson\u2019s disease. BMC Med. 2011;9:50.","journal-title":"BMC Med"},{"issue":"7","key":"3324_CR93","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00259-009-1103-3","volume":"36","author":"F Squitieri","year":"2009","unstructured":"Squitieri F, Orobello S, Cannella M, Martino T, Romanelli P, Giovacchini G, et al. Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins. Eur J Nucl Med Mol Imaging. 2009;36(7):1113\u201320.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"3324_CR94","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/WNF.0b013e31821c31d8","volume":"34","author":"M Esmaeilzadeh","year":"2011","unstructured":"Esmaeilzadeh M, Kullingsj\u00f6 J, Ullman H, Varrone A, Tedroff J. Regional cerebral glucose metabolism after pridopidine (ACR16) treatment in patients with Huntington disease. Clin Neuropharmacol. 2011;34(3):95\u2013100.","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"3324_CR95","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1176\/jnp.23.2.jnp206","volume":"23","author":"LE Hjermind","year":"2011","unstructured":"Hjermind LE, Law I, J\u00f8nch A, Stokholm J, Nielsen JE. Huntington\u2019s disease: effect of memantine on FDG-PET brain metabolism? J Neuropsychiatry Clin Neurosci. 2011;23(2):206\u201310.","journal-title":"J Neuropsychiatry Clin Neurosci"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-016-3324-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-016-3324-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-016-3324-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T19:14:32Z","timestamp":1553627672000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-016-3324-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,22]]},"references-count":95,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["3324"],"URL":"https:\/\/doi.org\/10.1007\/s00259-016-3324-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,22]]}}}